Table 1 Patient characteristics, all subjects (N = 490)
From: Navigating veterans with an abnormal prostate cancer screening test: a quasi-experimental study
|  | Navigated (N = 245) | Control (N = 245) | p-value |
|---|---|---|---|
| Â | N(%) | N(%) | Â |
Age | Â | Â | 0.046 |
< 65Â years old | 142 (58) | 119 (49) | Â |
≥ 65 years old | 103 (42) | 126 (51) |  |
Range | 48-79 | 42-92 | Â |
Race/ethnicity | Â | Â | <0.0001 |
African American | 155 (63) | 177 (72) | Â |
White | 68 (28) | 37 (15) | Â |
Other | 20 (8) | 7 (3) | Â |
Not reported | 2 (1) | 24 (10) | Â |
Comorbidities (CCI Score) | Â | Â | 0.72 |
0 | 96 (39) | 90 (37) | Â |
1-2 | 114 (47) | 123 (50) | Â |
> 2 | 35 (14) | 32 (13) | Â |
Screening eligibility | Â | Â | 0.058 |
PSA test (≥ 4.0 ng/mL) | 204 (83) | 210 (86) |  |
Abnormal PSA velocity | 26 (11) | 13 (5) | Â |
Abnormal (DRE) | 15 (6) | 22 (9) | Â |
Baseline PSA | Â | Â | 0.011 |
< 4Â ng/mLa | 26 (11) | 11 (5) | Â |
4Â ng/mL - 10Â ng/mL | 164 (71) | 154 (69) | Â |
> 10Â ng/mL | 40 (17) | 58 (26) | Â |
Missing (Eligible by DRE) | 15 (6) | 22 (9) | Â |
Cancer diagnosis | Â | Â | 0.54 |
No cancer/resolved with PSA test | 127 (52) | 117 (48) | Â |
Cancer | 84 (34) | 86 (35) | Â |
Unresolved | 34 (14) | 42 (17) | Â |